AN UNBIASED VIEW OF TOFACITINIB

In 2010, Ariad declared final result from a phase I analyze of ponatinib in people with resistant and refractory Continual myeloid leukemia and Philadelphia-beneficial acute lymphoblastic leukemia (Ph+ ALL).Afatinib belongs to a class of medicine called tyrosine kinase inhibitors. A category of medicine is a bunch of prescription drugs that do the